Pharma Mar Balance Sheet Health
Financial Health criteria checks 4/6
Pharma Mar has a total shareholder equity of €193.4M and total debt of €39.9M, which brings its debt-to-equity ratio to 20.6%. Its total assets and total liabilities are €340.5M and €147.1M respectively.
Key information
20.6%
Debt to equity ratio
€39.86m
Debt
| Interest coverage ratio | n/a |
| Cash | €162.56m |
| Equity | €193.44m |
| Total liabilities | €147.08m |
| Total assets | €340.52m |
Recent financial health updates
Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25
Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Recent updates
Pharma Mar, S.A. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 03Here's Why Pharma Mar (BME:PHM) Has A Meaningful Debt Burden
Jan 25Pharma Mar, S.A. (BME:PHM) Shares Could Be 30% Below Their Intrinsic Value Estimate
Apr 28We Believe That Pharma Mar's (BME:PHM) Weak Earnings Are A Good Indicator Of Underlying Profitability
Mar 08Analyst Forecasts Just Became More Bearish On Pharma Mar, S.A. (BME:PHM)
Mar 05Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
Feb 09We Think Pharma Mar (BME:PHM) Can Manage Its Debt With Ease
Oct 27An Intrinsic Calculation For Pharma Mar, S.A. (BME:PHM) Suggests It's 21% Undervalued
Sep 27Does Pharma Mar (BME:PHM) Have A Healthy Balance Sheet?
Jul 15Growth Investors: Industry Analysts Just Upgraded Their Pharma Mar, S.A. (BME:PHM) Revenue Forecasts By 24%
May 04Pharma Mar (BME:PHM) Has A Pretty Healthy Balance Sheet
Apr 11There Is A Reason Pharma Mar, S.A.'s (BME:PHM) Price Is Undemanding
Mar 16Is Pharma Mar (BME:PHM) Using Too Much Debt?
Jan 09Pharma Mar (BME:PHM) Seems To Use Debt Quite Sensibly
Sep 08News Flash: Analysts Just Made A Meaningful Upgrade To Their Pharma Mar, S.A. (BME:PHM) Forecasts
Aug 03Here's Why I Think Pharma Mar (BME:PHM) Is An Interesting Stock
May 31Pharma Mar (BME:PHM) Has A Rock Solid Balance Sheet
May 10Is Pharma Mar, S.A. (BME:PHM) Expensive For A Reason? A Look At Its Intrinsic Value
Apr 08Announcing: Pharma Mar (BME:PHM) Stock Increased An Energizing 231% In The Last Five Years
Jan 14Is Pharma Mar (BME:PHM) A Risky Investment?
Nov 19Financial Position Analysis
Short Term Liabilities: PHM's short term assets (€252.6M) exceed its short term liabilities (€95.9M).
Long Term Liabilities: PHM's short term assets (€252.6M) exceed its long term liabilities (€51.2M).
Debt to Equity History and Analysis
Debt Level: PHM has more cash than its total debt.
Reducing Debt: PHM's debt to equity ratio has reduced from 534.6% to 20.6% over the past 5 years.
Debt Coverage: PHM's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: Insufficient data to determine if PHM's interest payments on its debt are well covered by EBIT.